Chronic dry eye is highly prevalent and has a significant impact, yet it is simultaneously underdiagnosed, underappreciated, and undertreated, said Christopher J. Rapuano, MD, co-director of the refractive surgery department, Wills Eye Hospital, Philadelphia
Short-term use of topical steroids used in conjunction with other long-term therapies can help heal the ocular surface in patients considering refractive surgery, said Deepinder K. Dhaliwal, MD, of the University of Pittsburgh School of Medicine.
Albany, NY—Multicenter data indicate that the Dohlman-Doane type I (Boston) keratoprosthesis is a viable option for visual rehabilitation in eyes in which multiple penetrating keratoplasties have failed or that have a poor prognosis for primary keratoplasty, said Mich?l W. Belin, MD.
Los Angeles—The rates of infection after cataract surgery can be reduced by a meticulous approach to controlling the microbes on the ocular surface and in the eye. The use of fourth-generation fluoroquinolones can better control the microorganisms that have grown resistant to previous generations of the drugs.
MRI is in general superior to CT for neuro-ophthalmic indications. A CT study, however, might be useful [under certain circumstances].
New York—Several options can be offered to refractive surgery patients who are candidates for surface ablation procedures, and those individuals should be informed about differences between procedures with respect to speed of visual rehabilitation and postoperative comfort, said Gary R. Fishman, MD.
Boston—Global bio-nanotech company pSivida Ltd. has begun a phase II clinical trial of the steroid receptor antagonist mifepristone (RU486) as an eye-drop treatment for steroid-associated elevated IOP. The investigator-sponsored trial is expected to involve up to 45 patients in the United States.